Intended Retirement of Independent Non-executive Director and changes of composition of board committees
Rhea-AI Summary
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) announced that Professor Mok Shu Kam, Tony will retire and not seek re-election at the AGM on May 12, 2026, ceasing his role as Independent Non-executive Director and as chair/member of board committees due to nearing the nine-year tenure cap under Hong Kong Listing Rules.
Effective at the conclusion of the AGM and subject to re-election of directors, the Board approved committee changes: Dr Renu Bhatia appointed Senior and Lead Independent Non-executive Director and Nomination Committee chair; Dr Chaohong Hu appointed Technical Committee chair; and Professor Tan Shao Weng, Daniel joined the Sustainability Committee.
Positive
- Orderly succession: committee roles reassigned effective at AGM
- Internal continuity: three existing independent directors assume new committee leadership
- Compliance: retirement aligns with Hong Kong Listing Rules nine-year tenure guidance
Negative
- Loss of senior expertise: Professor Mok departs after eight-plus years
- Potential gap in scientific leadership: chair of Technical Committee role transferred
News Market Reaction – HCM
On the day this news was published, HCM declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: INDV up 1.52%, while BHC, KNSA, SUPN and PBH are modestly negative. With no peers in the momentum scanner and HCM up 1.5%, today’s action appears more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 04 | Clinical trial start | Positive | +1.2% | Initiation of Phase I/IIa trial for ATTC candidate HMPL-A580 in solid tumors. |
| Feb 06 | Earnings scheduling | Neutral | +4.2% | Announcement of date and webcast details for 2025 final results release. |
| Jan 13 | Clinical data publication | Positive | +2.3% | Publication of Phase III SACHI results in The Lancet for savolitinib combo. |
| Jan 06 | Phase III topline | Positive | +6.6% | Phase III ESLIM-02 trial of sovleplenib met primary endpoint in wAIHA. |
| Jan 04 | Trial progression | Positive | -2.0% | Initiation of Phase III stage of S+C+AG regimen in pancreatic cancer. |
Recent HUTCHMED news, especially positive clinical and pipeline milestones, has generally seen aligned positive price reactions, with one notable divergence on a strong clinical update.
Over recent months, HUTCHMED has reported several clinical and pipeline milestones, including Phase III results for sovleplenib in wAIHA and progression of combination trials such as surufatinib plus camrelizumab. It also initiated global studies of ATTC candidates like HMPL-A580 and scheduled release of 2025 final results on March 5, 2026. Most of these updates were followed by positive price moves. Today’s board and committee changes occur against this backdrop of active clinical development and regulatory progress.
Market Pulse Summary
This announcement details an intended retirement of a long-serving independent non-executive director at the May 12, 2026 AGM and a reallocation of key committee roles among existing independent directors. It signals adherence to the nine-year tenure cap under Hong Kong Listing Rules while maintaining continuity in governance. Investors may monitor how the new Senior and Lead Independent Director and committee chairs oversee scientific, nomination and sustainability agendas alongside HUTCHMED’s ongoing clinical and regulatory activities.
Key Terms
independent non-executive director financial
hong kong listing rules regulatory
AI-generated analysis. Not financial advice.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company.
In connection with the intended retirement of Professor Mok from the Board, the Board has approved the following changes to the composition of the board committees and the Senior and Lead Independent Non-executive Director of the Company, effective from the conclusion of the AGM, subject to the respective Directors being re-elected as Directors by the shareholders at the AGM:
(1) Dr Renu Bhatia will be appointed as the Senior and Lead Independent Non-executive Director, and appointed on the Nomination Committee as the chairman;
(2) Dr Chaohong Hu will be appointed as the chairman of the Technical Committee; and
(3) Professor Tan Shao Weng, Daniel will be appointed as a member of the Sustainability Committee.
Each of Dr Bhatia, Dr Hu and Professor Tan is currently an Independent Non-executive Director of the Company.
Dr Dan Eldar, the Chairman of HUTCHMED, said: “Professor Mok has served with distinction as an Independent Non-executive Director and as chairman of both the Nomination Committee and the Technical Committee. His leadership has been instrumental in strengthening the Board composition, and guiding the scientific and clinical development programs. His internationally recognized expertise in oncology has brought invaluable perspective to the long term strategy of the Company. The Board sincerely thanks Professor Mok for his significant contributions to the growth of the Company, and we wish him all the best in his future endeavours.”
Pursuant to the requirements of Rule 13.51(2) of the Hong Kong Listing Rules, Professor Mok has confirmed that he has no disagreement with the Board and that there are no other matters that need to be brought to the attention of the shareholders of the Company in connection with his retirement from the Board.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, the risk that current or future appointees to HUTCHMED’s board of directors are not effective in their respective positions, the difficulty in locating and recruiting suitable candidates for its board of directors and the management difficulties which may arise from changes in HUTCHMED’s board of directors. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, on AІM and with The Stock Exchange of Hong Kong Limited. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
FAQ
Why is Professor Mok Shu Kam retiring from HUTCHMED (HCM) at the AGM on May 12, 2026?
Who will replace Professor Mok as Senior and Lead Independent Non-executive Director of HUTCHMED (HCM)?
What committee changes will HUTCHMED (HCM) implement after Professor Mok's retirement?
Does Professor Mok have any disagreement with HUTCHMED (HCM) over his retirement announcement?
How might the board changes announced by HUTCHMED (HCM) affect governance continuity?
